Nonsteroidal anti-inflammatory drug-related gastrointestinal bleeding in the elderly

International Journal of Gerontology

Volumn 1, Issue 1, 2007, Pages 40-45

  Shih, Shou Chuan ^a,b,c   Chang, Chen Wang ^a  

^a Division of Gastroenterology   (Taiwan)

^b MACKAY MEMORIAL HOSPITAL   (Taiwan)

^c NURSING AND MANAGEMENT COLLEGE   (Taiwan)

Author keywords

Elderly; Gl bleeding; NSAID

Indexed keywords

ACETYLSALICYLIC ACID; BENZODIAZEPINE DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; CIMETIDINE; CYCLOOXYGENASE 2 INHIBITOR; CYTOCHROME P450; HISTAMINE H2 RECEPTOR ANTAGONIST; MEVINOLIN; MISOPROSTOL; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR; ROFECOXIB; SUCRALFATE; VALDECOXIB;

ARTHRITIS; BARIUM ENEMA; CAPSULE ENDOSCOPY; CARDIOVASCULAR DISEASE; DIGESTIVE SYSTEM INJURY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DUODENOGASTRIC REFLUX; ENZYME METABOLISM; ENZYME REPRESSION; ERADICATION THERAPY; ESOPHAGOGASTRODUODENOSCOPY; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; GERIATRIC CARE; HEALTH CARE PERSONNEL; HELICOBACTER PYLORI; HUMAN; OCCULT BLOOD; PATHOGENESIS; PEPTIC ULCER BLEEDING; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; REVIEW; UNSPECIFIED SIDE EFFECT;

EID: 39549101210     PISSN: 18739598     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1873-9598(08)70022-X     Document Type: Review

References (42)

1. Greenwald DA. Aging, the gastrointestinal tract, and risk of acid-related disease. Am J Med 2004; 117: 8S-13S.
2. Lassen A, Hallas J, Schaffalitzky de Muckadell OB. Complicated and uncomplicated peptic ulcers in a Danish county 1993-2002: a population-based cohort study. Am J Gastroenterol 2006; 101: 945-53.
3. Garcia Rodriguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994; 343: 769-72.
4. Griffin MR, Piper JM, Daugherty JR, Snowden M, Ray WA. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med 1991; 114: 257-63.
5. Solomon DH, Glynn RJ, Bohn R, Levin R, Avorn J. The hidden cost of nonselective nonsteroidal antiinflammatory drugs in older patients. J Rheumatol 2003; 30: 792-8.
6. Terrell KM, Heard K, Miller DK. Prescribing to older ED patients. Am J Emerg Med 2006; 24: 468-78.
7. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999; 340: 1888-99.
8. Linder JD, Wilcox CM. Acid peptic disease in the elderly. Gastroenterol Clin North Am 2001; 30: 363-76.
9. Papatheodoridis GV, Sougioultzis S, Archimandritis AJ. Effects of Helicobacter pylori and nonsteroidal anti-inflammatory drugs on peptic ulcer disease: a systematic review. Clin Gastroenterol Hepatol 2006; 4: 130-42.
10. Allen A, Flemstrom G. Gastroduodenal mucus bicarbonate barrier: protection against acid and pepsin. Am J Physiol Cell Physiol 2005; 288: C1-19.
11. Halter F. Mechanism of gastrointestinal toxicity of NSAIDs. Scand J Rheumatol Suppl 1988; 73: 16-21.
12. Cryer B. Mucosal defense and repair. Role of prostaglandins in the stomach and duodenum. Gastroenterol Clin North Am 2001; 30: 877-94.
13. Wilson DE. Role of prostaglandins in gastroduodenal mucosal protection. J Clin Gastroenterol 1991; 13 (Suppl 1): S65-71.
14. Arya N, Rossos PG. Prevention of NSAID-related gastrointestinal complications in the geriatric patient. Geriatr Aging 2002; 5: 28-31.
15. Haykey CJ. Nonsteroidal anti-inflammatory drug gastropathy. Gastroenterology 2000; 119: 521-35.
16. Choudari CP, Elton RA, Palmer KR. The outcome of peptic ulcer haemorrhage in relation to consumption of non-steroidal anti-inflammatory drugs or aspirin. Aliment Pharmacol Ther 1994; 8: 457-60.
17. Ng W, Wong WM, Chen WH, Tse HF, Lee PY, Lai KC, et al. Incidence and predictors of upper gastrointestinal bleeding in patients receiving low-dose aspirin for secondary prevention of cardiovascular events in patients with coronary artery disease. World J Gastroenterol 2006; 12: 2923-7.
18. Laine L. Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology 2001; 120: 594-606.
19. Armstrong CP, Blower AL. Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulceration. Gut 1987; 28: 527-32.
20. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med 1991; 115: 787-96.
21. Geyer M, Stamenic I, Buhler H, Bertschinger P. Epidemiology of gastrointestinal bleeding in the elderly. Schweiz Rundsch Med Prax 2006; 95: 757-65.
22. Hallas J, Lauritsen J, Villadsen HD, Gram LF. Nonsteroidal anti-inflammatory drugs and upper gastrointestinal bleeding, identifying high-risk groups by excess risk estimates. Scand J Gastroenterol 1995; 30: 438-44.
23. Mitchell SH, Schaefer DC, Dubagunta S. A new view of occult and obscure gastrointestinal bleeding. Am Fam Physician 2004; 69: 875-81.
24. Hayashi Y, Yamamoto H, Kita H, Sunada K, Sato H, Yano T, et al. Non-steroidal anti-inflammatory drug-induced small bowel injuries identified by double-balloon endoscopy. World J Gastroenterol 2005; 11: 4861-4.
25. Meddings JB, Sutherland LR, Byles NI, Wallace JL. Sucrose: a novel permeability marker for gastroduodenal disease. Gastroenterology 1993; 104: 1619-26.
26. Rabassa AA, Goodgame R, Sutton FM, Ou CN, Rognerud C, Graham DY. Effects of aspirin and Helicobacter pylori on the gastroduodenal mucosal permeability to sucrose. Gut 1996; 39: 159-63.
27. Goldstein JL, Aisenberg J, Lanza F, Schwartz H, Sands GH, Berger MF, et al. A multicenter, randomized, double-blind, active-comparator, placebo-controlled, parallel-group comparison of the incidence of endoscopic gastric and duodenal ulcer rates with valdecoxib or naproxen in healthy subjects aged 65 to 75 years. Clin Ther 2006; 28: 340-51.
28. Pilotto A, Franceschi M, Vitale DF, Zaninelli A, Masotti G, Rengo F, et al. Upper gastrointestinal symptoms and therapies in elderly out-patients, users of non-selective NSAIDs or coxibs. Aliment Pharmacol Ther 2005; 22: 147-55.
29. Scheiman JM. Unmet needs in non-steroidal anti-inflammatory drug-induced upper gastrointestinal diseases. Drugs 2006; 66 (Suppl 1): 15-21.
30. Cozzarini W, Rath J, Bauer A, Gvorog I, Gvorog M, Prenner M, et al. Mucosa protective therapy with long-term nonsteroidal antirheumatic drugs. Wien Med Wochenschr 2003; 153: 295-303.
31. Sung JJ. Management of nonsteroidal anti-inflammatory drug-related peptic ulcer bleeding. Am J Med 2001; 110(1A): 29S-32S.
32. Caldwell JR, Roth SH, Wu WC, Semble FL, Castell DO, Heller MD, et al. Sucralfate treatment of nonsteroidal anti-inflammatory drug-induced gastrointestinal symptoms and mucosal damage. Am J Med 1987; 83: 74-82.
33. Miglioli M, Bianchi Porro G, Vaira D, Menegatti M, Brunetti G, Petrillo M, et al. Prevention with sucralfate gel of NSAID-induced gastroduodenal damage in arthritic patients. Am J Gastroenterol 1996; 91: 2367-71.
34. Kurosawa S. What is important in treating elderly with H2 receptor antagonists. Nippon Rinsho 2002; 60: 1613-7.
35. Lanas A, Rodrigo L, Marquez JL, Bajador E, Perez-Roldan F, Cabrol J, et al. Low frequency of upper gastrointestinal complications in a cohort of high-risk patients taking low-dose aspirin or NSAIDS and omeprazole. Scand J Gastroenterol 2003; 38: 693-700.
36. Lanas A, Ferrandez A. NSAID-induced gastrointestinal damage: current clinical management and recommendations for prevention. Chin J Dig Dis 2006; 7: 127-33.
37. Pilotto A, Franceschi M, Leandro G, Paris F, Cascavilla L, Longo MG, et al. Proton-pump inhibitors reduce the risk of uncomplicated peptic ulcer in elderly either acute or chronic users of aspirin/non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2004; 20: 1091-7.
38. Chan FK, Chung SC, Suen BY, Lee YT, Leung WK, Leung VK, et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 2001; 344: 967-73.
39. Gisbert JP, Khorrami S, Carballo F, Calvet X, Gene E, Dominguez-Munoz E. Meta-analysis: Helicobacter pylori eradication therapy vs. antisecretory non-eradication therapy for the prevention of recurrent bleeding from peptic ulcer. Aliment Pharmacol Ther 2004; 19: 617-29.
40. Giral A, Ozdogan O, Celikel CA, Tozun N, Ulusoy NB, Kalayci C. Effect of Helicobacter pylori eradication on anti-thrombotic dose aspirin-induced gastroduodenal mucosal injury. J Gastroenterol Hepatol 2004; 19: 773-7.
41. Hunt RH, Bazzoli F. Review article: should NSAID/low-dose aspirin takers be tested routinely for H. pylori infection and treated if positive? Implications for primary risk of ulcer and ulcer relapse after initial healing. Aliment Pharmacol Ther 2004; 19 (Suppl 1): 9-16.
42. Chan FK. NSAID-induced peptic ulcers and Helicobacter pylori infection: implications for patient management. Drug Saf 2005; 28: 287-300.